Current Report Filing (8-k)
January 30 2018 - 3:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 29th, 2018
CANNABICS PHARMACEUTICALS INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
000-52403
|
20-3373669
|
(State of incorporation)
|
(Commission File Number)
|
(IRS Employer No.)
|
#3 Bethesda Metro Center
Suite 700
Bethesda, Md 20814
(Address of principal executive offices
and Zip Code)
877-424-2429
(Registrant's telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 5.02 – DEPARTURE OF DIRECTORS
OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
On
January 29
th
, 2018, Itamar Borochov
stepped down as Director and CEO of the Company. His resignation was not
the result of any dispute with the Corporation. On the same date, the shareholders of the Corporation elected Ehud Rieger to the
position of Director and Board Member. Additionally, the shareholders elected current Director and COO Eyal Barad to the position
of CEO.
Eyal
Barad 52, is a co-founder of Cannabics Inc., founded in 2012, and is a core member of Cannabics Inc.’s management team and
brings 20 years of executive managerial experience in successful technology and startup ventures. Mr. Barad received his BA in
Economics & International Relations from the Hebrew University in Jerusalem in 1994, and an MBA with Honors from Haifa University
in 2007.
Ehud
Rieger, 56, brings 30 years of executive corporate experience, is Manager of Alrig Investments & Finance Ltd. since 1991, and
is a Board Member of several private and public companies. He held the rank of Major in the Israeli Defense Forces. Ehud obtained
his Law Degree from Tel Aviv University in 1989, and MBA at INSEAD in Fontainebleau, France, in 1990.
Related
Party – Both Barad and Rieger are shareholders of Cannabics Inc., a Delaware corporation and majority shareholder of the
Company.
ITEM 9.01 FINANCIAL STATEMENTS &
EXHIBITS
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 30, 2018
|
Cannabics Pharmaceuticals Inc.
|
|
|
|
|
|
By:
/s/ Eyal Barad
|
|
Eyal Barad, Director, CEO
|
CNBX Pharmaceuticals (QB) (USOTC:CNBX)
Historical Stock Chart
From Mar 2024 to Apr 2024
CNBX Pharmaceuticals (QB) (USOTC:CNBX)
Historical Stock Chart
From Apr 2023 to Apr 2024